Syndax pipeline update: Revuforj and Niktimvo catalysts to watch
Decision brief
Answer first · skim in under a minute
This Syndax pharmaceuticals news plan focuses on the company’s approved assets, revumenib and axatilimab, and the next clinical catalysts that matter to analysts. It is built to support competitive benchmarking, FDA context, and investment-useful follow-up.
Syndax pharmaceuticals news in 2025–2026 centers on two marketed oncology assets: Revuforj (revumenib), a menin inhibitor with an expanded AML label, and Niktimvo (axatilimab-csfr), a CSF-1R blocker for chronic graft-versus-host disease after prior systemic therapy failure.
Contents11 sections
Key Takeaways
- FDA approved revumenib (Revuforj) on 24 October 2025 for R/R AML with susceptible NPM1 mutation (patients ≥1 year) when no satisfactory alternatives exist.
- Earlier Revuforj approval (2024) covered R/R acute leukemia with KMT2A translocation; Snapshots cite AUGMENT-101 (NCT04065399).
- Niktimvo is FDA-approved for chronic GVHD after ≥2 prior systemic therapies; Incyte/Syndax announced 9 mg and 22 mg vials on 15 January 2025.
- NPM1 cohort CR+CRh rate was 23.1% (95% CI 13.5–35.2) with median duration 4.5 months per FDA summary.
What did FDA approve for Revuforj in October 2025?
On 24 October 2025 FDA approved revumenib for relapsed/refractory AML with a susceptible NPM1 mutation in patients one year and older lacking satisfactory alternatives. Efficacy came from AUGMENT-101 (NCT04065399).
FDA reported CR+CRh 23.1% (95% CI 13.5–35.2) and median CR+CRh duration 4.5 months (95% CI 1.2–8.1). Among 46 transfusion-dependent patients at baseline, 8 (17%) became transfusion-independent in a 56-day window.
How does the KMT2A label differ?
FDA Drug Trials Snapshots for REVUFORJ summarize the 15 November 2024 KMT2A translocation approval based on AUGMENT-101 evidence in 104 efficacy patients. Keep NPM1 and KMT2A cohorts distinct when modeling uptake.
What is the Niktimvo catalyst path?
Incyte and Syndax’s 15 January 2025 release said FDA approved 9 mg and 22 mg vial sizes, with U.S. availability expected early February 2025. First approval was 14 August 2024 for chronic GVHD after ≥2 prior systemic therapies (≥40 kg).
AGAVE-201 supported approval; the release cites 75% of patients on 0.3 mg/kg every two weeks achieving a response at six months (N=79).
Which commercial metrics are company-reported only?
Syndax’s FY2025 update claimed over $275 million in 2025 combined product sales. Treat that as company guidance until SEC filings confirm line-item revenue.
What should teams watch next?
Watch post-transplant Revuforj use, NPM1 launch uptake, Niktimvo vial conversion, and new menin or CSF-1R combination registrations on ClinicalTrials.gov.
What remains unproven for Syndax catalysts?
Long-term survival beyond CR/CRh duration, real-world transfusion independence, and share versus other menin inhibitors are still unfolding. Do not invent peak-sales figures.
How should Syndax pharmaceuticals news feed 2026 models?
Syndax pharmaceuticals news after the 24 October 2025 NPM1 approval should split KMT2A (15 November 2024) and NPM1 cohorts. Use CR+CRh 23.1%, median 4.5 months, and the 17% transfusion-independence conversion (8 of 46) as base-case efficacy anchors, then stress-test 2026 uptake if real-world duration falls below 4.5 months.
For Niktimvo, keep the 14 August 2024 initial approval, the 15 January 2025 9 mg/22 mg vial decision, and the AGAVE-201 75% six-month response (N=79) on the 0.3 mg/kg q2w cohort as labeled facts—not as peak-share proofs.
Related NovaPharma coverage
Frequently Asked Questions
What is Revuforj (revumenib)?
Revuforj is an oral menin inhibitor FDA-approved for R/R acute leukemia with KMT2A translocation and, as of 24 October 2025, for R/R AML with a susceptible NPM1 mutation in patients one year and older when alternatives are inadequate.
What trial supports the NPM1 AML approval?
SNDX-5613-0700 / AUGMENT-101 (NCT04065399). FDA reported a CR+CRh rate of 23.1% and median CR+CRh duration of 4.5 months in the NPM1 cohort.
What is Niktimvo used for?
Niktimvo (axatilimab-csfr) is a CSF-1R-blocking antibody approved for chronic GVHD after failure of at least two prior systemic therapies in patients weighing at least 40 kg.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for revumenib.
Unlock full calendar →Syndax Pharmaceuticals pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
